In the models assessed, aPD-1+aLAG-3 ICB in combination with anti-metabolite chemotherapy improves anti-tumor immunity by increasing CD8+ T-cell proliferation and DCs proportions in tumors and DLNs. This evidence concerns the gene CD8A and neoplasm.